8月31日，Ascendis Pharma盘中上涨5.92%，报262.0美元/股，成交额3316.58万美元。
消息面上，公司宣布与BioMarin签署具有约束力的条款清单，就Yuviwel（Navepegritide）达成全球和解及许可协议，终结双方在美国、德国、丹麦、巴西及韩国的所有专利诉讼。根据协议，Ascendis将就美国净销售额支付20%的特许权使用费，欧盟、巴西及韩国销售额支付18%，期限至2030年5月，许可覆盖包括软骨发育不全在内的所有现有及未来适应症。BioMarin亦将撤销ITC调查。
此前市场对Yuviwel的知识产权不确定性持续担忧，此次和解彻底消除了该产品的专利诉讼风险。Yuviwel自获FDA加速批准并于美国商业化上市以来，患者入组已超220例，处方医生超100名，商业放量势头良好，和解落地进一步扫清其全球推广障碍。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.